Global Botulinum Toxin Market By Product Type (Type A and Type B), By Application (Aesthetic and Therapeutic), By End-User (Hospitals, Dermatology Clinics, and Spas & Cosmetic Centers), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The Global Botulinum Toxin Market size is expected to be worth around USD 13.4 Billion by 2032, from USD 6.1 Billion in 2022, growing at a CAGR of 8.4% during the forecast period from 2023 to 2032.

The bacterium Clostridium botulinum produces botulinum toxin, a protein, and neurotoxin. When injected into the muscle, the toxin blocks neural transmission by selectively blocking the release of acetylcholine from nerves. One of the unique substances ever discovered in medicine and science is botulinum toxin. Over the past ten years, in cosmetology, the use of botulinum toxin has grown-up rapidly, and it is widely performed and one of the most common aesthetic procedures worldwide.

Cosmetic procedures have increased as a result of growing concerns about one’s appearance in both developing and developed countries. The market’s expansion will be sped up by the accessibility of different types of botulinum toxin products like Xeomin, Botox, and Disport. Over the next few years, the market is expected to expand due to the growing use of botulinum toxin injection in a variety of aesthetic procedures, such as the treatment of chemical browlifts, glabellar lines, and forehead lines.

Key Takeaways

• Based on Product Type, the type A segment accounted for the largest market share in 2022 and is expected to grow more over the forecast period from 2023 to 2032.
• Based on Applications, the therapeutic segment held the largest share globally in 2022 and is projected to expand significantly during the forecast period from 2023 to 2032.
• By End-User, the hospital’s segment dominated the global market in 2022.
• In 2022, North America dominated the market with the highest revenue share of 39.0%.
• Asia-Pacific will likely grow at the fastest CAGR from 2023-2032.

Product Type Analysis

The Type A Segment held the largest market share in 2022

Based on product, the global botulinum toxin market is categorized into type A and type B. With the largest revenue share in 2022, the botulinum toxin type-A segment is expected to expand at a substantial rate over the forecast period due to customer preference for benefits like no blood loss, minimal pain, and no scarring. Botulinum toxin type A has been gradually used to treat primary neurological disorders like tension-type headaches and chronic migraines.

Botulinum toxin type A products are used for a variety of aesthetic and therapeutic purposes. This market is expected to expand more in the future due to the rising demand for aesthetic beauty. Additionally, a number of commercially available botulinum toxin type-A products, such as Dysport and Botox, have been clinically tested and found to be safe, long-lasting, and free of side effects.

Application Analysis

The therapeutic segment dominated the global botulinum toxin market in 2022

Based on application, the market for botulinum toxin is divided into aesthetic and therapeutic. With a revenue share of more than 50% in 2022, the therapeutic segment dominated the market. The most powerful biological molecule known is botulinum toxin, which holds great potential for treating numerous disorders.

Due to a deeper comprehension of its various mechanisms of action and molecular behavior, the therapeutic benefits of botulinum toxin have expanded. Botox procedures are used for a variety of therapeutic and preventive treatments for conditions like hyperhidrosis, overactive bladders, and chronic migraines.

During the forecast period, it is anticipated that the aesthetic market will increase at a noteworthy CAGR. A staple of the beauty industry’s arsenal is botulinum toxin (BoNT), a neurotoxin that is produced by bacteria. In both developed and developing nations, an increase in the demand for cosmetic surgeries is the result of a growing awareness of how one should look and of technological advancements.

End-User Analysis

The hospital’s segment accounted for the highest revenue share in 2022

Based on end-user, the global botulinum toxin market is classified into hospitals, dermatology clinics, and spas & cosmetic centers. In 2022, the hospital’s segment had the highest revenue share. The segment’s expansion is aided by an increase in the number of hospitals offering cutting-edge services and facilities in both developed and developing nations as well as public awareness of aesthetic procedures.

In addition, hospitals perform the majority of therapeutic procedures for chronic migraine, dystonia, and spasticity. From 2023 to 2032, the spas and cosmetic centers market is expected to grow at a significant CAGR. The dermatology, spa, and cosmetic centers’ increased preference for aesthetic procedures is a significant factor in the segment’s expansion.

Medical spa owners and plastic surgeons are experiencing growth in business. Additionally, the market’s expansion is aided by the increasing number of medical spas and cosmetic centers in Asia-Pacific.

Key Market Segments

By Product Type

• Type A
• Type B 

By Application

• Aesthetic
• Therapeutic

By End-User

• Hospitals
• Dermatology Clinics
• Spas & Cosmetic Centers

Drivers

Increase in Healthcare Spending

Increase in healthcare spending, availability of numerous products, and rising use of botulinum injections are subjected to drive the market growth.

The botulinum toxin market is also being driven by the existence of promising candidates in the pipeline, rising costs, changes to reimbursement policies to support botulinum injections, and increased spending on healthcare infrastructure construction.

The cost of botulinum toxin injections is influenced by a number of factors, including how far along the fine lines and wrinkles are, how actively people want to treat the problematic areas, and, consequently, the bulk of product used. The availability of numerous products, such as Dysport, Botox, and Xeomin, will also accelerate the industry’s growth.

Additionally, it is anticipated that the increasing usage of botulinum toxin injection in various types of cosmetic procedures, including the treatment of perioral, chemical browlift, glabellar, and periorbital lines, will accelerate the market share of botulinum toxin in the years to come. The provider’s non-invasive technologies and dermatological procedures that needed minimally invasive cosmetic operations were severely impacted by the spike.

In order to meet the growing demand for these medications, a number of active pharmaceutical companies are gradually developing products. One of the most popular and widely used aesthetic procedures across the globe, botulinum toxin has seen rapid expansion in the cosmetology field over the past ten years. In both developed and developing nations, the number of cosmetic procedures has led to an increase in aesthetic concerns.

Restraints

High Cost Of Botulinum Toxin Operations And Botulinum Injection

The high cost of botulinum toxin operations and botulinum injection side effects may restrain the botulinum toxin market growth. In the time frame that is anticipated, market expansion may be hindered by the high cost of botulinum toxin operations. The fact that these procedures are not widely available to lower-income individuals in emerging nations may limit market expansion opportunities.

The development of the global botulinum toxin market is anticipated to be hampered by patient botulinum toxin injection side effects such as rash, allergic reactions, difficulty in swallowing, neck and back pain, nausea, and shortness of breath. The spread of the toxin throughout the body can result in potentially fatal symptoms like systemic anaphylactic reactions or botulism-like symptoms. Botulinum toxin is rarely used for cosmetic purposes without causing significant adverse effects.

Opportunity

Rising Investment Opportunities

Rising investment in R&D initiatives provides opportunities for therapeutic applications for the expansion of the global botulinum toxin market.

The demand for non-invasive surgical procedures, and cosmetics, the introduction of new products, modifications to reimbursement policies to include botulinum injections, and an improvement in affordability, are all contributing to the expansion of the global botulinum toxin market.

There are seven distinct antigenic forms of the neurotoxin Botulinum Toxin (BNT): Clostridium botulinum is an anaerobic bacterium that produces BNT-A, B, C, D, E, F, and G, which are frequently utilized in cosmetics. There are currently only a few BNT-A products and one BNT-B product available for purchase.

Trends

Rising demand for high-end beauty products

Botulinum toxin A products have benefited greatly from the rising demand for high-end beauty products all over the world. Additionally, the healthcare platform has provided opportunities for expansion due to the therapeutic applications of botulinum toxins.

While women account for more than 90% of all cosmetic procedures worldwide, men account for only 8 to 10% of all procedures. Over-40s are concerned about how they look and want to appear younger. As a direct result of this, they are putting a greater emphasis on the cosmetic features that women, particularly in developed nations, prefer.

Regional Analysis

North America dominated the botulinum toxin market with maximum shareholding in 2022

Based on region, the market for botulinum toxin is classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Due to rising disposable income and an increasing number of cosmetic procedures, North America had the largest revenue share in 2022, with 39.0%. For instance, according to the American Society of Plastic Surgeons (ASPS), botulinum toxin products were used in 1.3 to 1.5 million surgeries in 2019. As a result, the North American market will expand as more botulinum toxin products are used in cosmetic procedures executed in the region.

Due to a large patient population, favorable reimbursement, and the availability of advanced healthcare facilities in many nations, the Asia-Pacific region is anticipated to experience the highest CAGR during the forecast period.

The market is likely to be driven by a higher level of beauty and aesthetic consciousness in China, Japan, and South Korea. In addition, the market in the region is anticipated to be driven by the increasing number of medical spas and cosmetic centers in nations like Singapore, Thailand, and Malaysia.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The global market is highly regulated and competitive. To consolidate their position and gain a significant share of the market, the major players in the sector are adopting essential business strategies like product innovations, strategic partnerships and collaborations, new product launches, advanced service launches, joint ventures, and contracts. Listed below are some of the major players in the botulinum toxin market.

Market Key Players

• Ipsen Pharma
• AbbVie Inc.
• Medy-Tox, Inc.
• Merz Pharma
• US Worldmeds
• Evolus, Inc.
• Galderma
• Metabiologics Inc.
• Lanzhou Institute of Biological Products co.
• Tenjin Pharma
• Eisai Co., Ltd.
• Anika Therapeutics, Inc.
• Hugh Source International Ltd
• Revance Therapeutics
• Daewoong Pharmaceuticals
• Other Key Players

Recent Developments

• July 2024: Merz Aesthetics announced that the U.S. Food and Drug Administration (FDA) approved XEOMIN® as the first and only neurotoxin for the simultaneous treatment of three areas of the upper face: forehead lines, frown lines, and crow’s feet. This approval marked a significant advancement in the therapeutic applications of XEOMIN®, allowing for a broader range of aesthetic treatments.
• January 2024: Ipsen Pharma reported results from the AboLiSh study during the TOXINS 2024 conference, showcasing the effectiveness of Dysport (abobotulinumtoxinA) with injection guidance techniques for treating lower-limb spasticity. This study emphasized the clinical benefits and aimed to enhance therapeutic outcomes for patients.
• November 2023: AbbVie announced the acquisition of ImmunoGen for $10.1 billion, marking a significant expansion of its oncology franchise. This acquisition adds the advanced antibody-drug conjugate (ADC), Elahere, to AbbVie’s portfolio. Elahere, targeting platinum-resistant ovarian cancer, received accelerated approval from the FDA in November 2022. This move is expected to bolster AbbVie’s capabilities in solid tumors and hematologic malignancies, aligning with its growth strategy in oncology.

Report Scope